NimbleGen to discontinue IPO after Roche's $272.5 million acquisition
NimbleGen had sought to raise $75 million in the IPO, but un...Potawatomis complete acquisition of tech firm
OneProspect, which had been a business division of the Potawatomi Busin...GE acquisition may boost "early" healthcare strategy
GE and Ab...Berbee believes acquisition by CDW will make it a national IT player
The acquisition, which has been approved by the boards of both companies, i...Some great insights into the current Mergers & Acquisitions Market
From topics such as "maximizing...NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
Deficit in NHS fund has lead to cancellation of subsidized flexible working for NHS doctors, the part-time flexible working scheme which was introduced four years back by the Government is being rolled back// due to financial crisis in the NHS fund. The Private hospitals have also showed interest to acquisition of NHS funded government hospitals which are working in a horrible situation d...Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
Leading biotech companies like Pfizer are increasingly interested in acquisition of smaller biotech companies whose products are in the early phase 2 clinical trials.// “Smaller companies are more willing to consider acquisition then they used to be,” notes Roger Longman, Managing Partner at Healthcare business information specialist for Windhover information. The possibilities of going p...Smoking Increases Risk of HIV Acquisition
Smoking is an independent risk factor for HIV infection, according to investigators from Sheffield, writing in the February edition of Sexually Transmitted Infections. The researchers conducted// a meta-analysis of studies exploring this issue. However, an analysis of studies looking at the link between smoking and progression to AIDS failed to find any link. There is a growing recogni...Roche Completes Acquisition of BioVeris
Roche Diagnostics today announces that it has completed its acquisition of BioVeris. Roche signed the merger agreement with BioVeris for approximately $600 million on April 4, 2007. This means Roche Diagnostics now owns the patents for Electrochemiluminescence (ECL) technology and can expand its immunochemistry business from the human diagnostics field into new market segments such...